Stock Analiz

Fortress Biotech, Inc. FBIO

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.88Market cap $63M
Open the interactive analysis →

Fortress Biotech, Inc. (FBIO) is a healthcare company listed in the US with a market value of about $63M. In the twelve months to September 30, 2026 it had revenue of $70M and net income of $92M, a net margin of 131.2%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is value (3/5); the weakest is track record (0/5).

Key numbers: a P/E of 0.7, 5-year revenue growth of 7% a year, a 5-year average ROIC of -88%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 439% above the current price.

About Fortress Biotech

Fortress Biotech is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $863000 in 2015 to $63M in 2025, growth of about 53.6% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 371% over three years (dilution for shareholders). It spends 19% of revenue on research and development.

Score: 1.6 / 5

Value3/5
Future growth2/5
Track record0/5
Financial health1/5
Shareholder returns2/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Pays a dividend
  • Dividend 3 years in a row

Checks not passed

  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)0.7
Forward P/E—
P/FCF—
P/S0.9
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price+439%

Growth and quality

Revenue growth (1 yr)9.7%
Revenue growth (5 yrs, per year)6.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-69.8%
ROIC (5-yr avg.)-88.2%
Profitable years (of last 10)1
Years paying a dividend6

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$70M$63M$58M$85M$76M$69M$46M$37M$27M$188M$16M
Net income$92M$7M-$46M-$61M-$87M-$65M-$47M-$40M-$84M-$67M-$55M
Free cash flow——-$80M-$128M-$182M-$121M-$86M-$97M-$106M-$82M-$52M
EPS (diluted)$2.72$-0.07$-2.69$-8.47$-15.97$-11.85$-9.75$-10.95$-29.10$-24.15$-20.70
Net margin131.2%10.8%-79.8%-71.8%-114.3%-94.1%-102.0%-109.1%-313.0%-35.6%-334.3%
ROIC—-58.9%-88.9%-107.9%-100.2%-84.9%-42.5%-81.7%-139.1%-59.1%-95.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $5.00, 166% above the current price; targets range from $5.00 to $5.00; the consensus rating is “none”; expected EPS is $2.55 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Fortress Biotech’s P/E ratio?

About 0.7, based on the last twelve months of diluted earnings per share.

Is Fortress Biotech stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 439% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Fortress Biotech pay a dividend?

Not currently.

Is Fortress Biotech a good stock to buy?

We do not give buy or sell advice. Fortress Biotech scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.